- +86 1872918458
- maggie@sinotcell.com
- High-tech Zone,Xi’an, Shaanxi, China
Understand the high-risk groups, early symptoms,and screening recommendations for hematologic malignancies,
early detection, early treatment
We focus on providing world-class diagnosis and treatment services for the following hematologic malignancy patients:
Newly diagnosed hematologic malignancy patients, seeking the best treatment plan
Relapsed/refractory patients, needing innovative treatment methods
Patients seeking CAR-T cell therapy and other internationally cutting-edge therapies
International patients who wish to receive high cost-effective and high-quality medical care in China
Patients and family members who need a second medical opinion
No matter which stage of the disease you are in, we will provide you with professional, comprehensive, and personalized medical services to help you regain health.
⚠️ Symptoms Requiring Immediate Medical Attention:
1.Initial Consultation
• Submit medical records to obtain a free medical evaluation
• The expert team conducts a remote consultation
• Determine whether the patient meets the conditions for CAR-T treatment
2.Admission Evaluation
• Comprehensive physical examination and laboratory tests
• Imaging evaluation (PET-CT, MRI, etc.)
• Cardiopulmonary function evaluation
• Infectious disease screening
3.Lymphocyte Collection
• Collect the patient’s peripheral blood mononuclear cells through a blood cell separator
• The collection process takes about 3–4 hours
• No hospitalization required, can be completed on an outpatient basis
4.CAR-T Cell Preparation
• The cells are genetically modified in a GMP laboratory
• The preparation period is about 1–2 weeks
• Strict quality control ensures safety
5.Lymphodepleting Chemotherapy
• Conducted 3–5 days before infusion
• Create the optimal expansion environment for CAR-T cells
• Commonly used FC regimen (Fludarabine + Cyclophosphamide)
6.CAR-T Cell Infusion
• Single intravenous infusion, about 30–60 minutes
• Closely monitor vital signs after infusion
• Hospital observation for at least 7–14 days
7.Acute Phase Monitoring (0–28 days after infusion)
• Closely monitor CRS and ICANS
• Daily laboratory tests
• Promptly manage adverse reactions
8.Long-term Follow-up
• Regularly evaluate efficacy (bone marrow puncture, imaging)
• Monitor long-term safety
• Provide continuous medical support
From evaluation to completion of infusion: about 4–6 weeks
Hospitalization time: about 2–4 weeks
Total cost: about 50–70% of that in European and American countries
At present, CAR-T therapy is mainly applicable to: relapsed/refractory B-ALL (up to 60), relapsed/refractory DLBCL (after at least 2 lines of treatment), and relapsed/refractory multiple myeloma (after at least 3 lines of treatment). It requires evaluation by a professional doctor.
Age is not an absolute contraindication. We have successfully performed CAR-T therapy for many patients over 70 years old. The key lies in the overall health condition and organ function evaluation.
In addition to CAR-T, there are multiple options such as bispecific antibodies, ADC drugs, novel targeted drugs, and allogeneic transplantation. We will formulate the best plan according to the patient’s specific condition.
We provide full-process services: medical visa assistance, medical record translation, airport pick-up and drop-off, accommodation arrangement, interpreter accompaniment, etc. Only complete medical records need to be brought.
Yes. We encourage family members to accompany the patient and provide accommodation arrangements for family members. During specific treatment stages (such as in a sterile laminar flow ward), visitation may need to be restricted.
Comprehensive analysis of disease types, diagnostic methods, and treatment options
Top medical team, advanced equipment, successful cases
How CAR-T helps hematologic malignancy patients regain new life？
24-hour professional consultation to formulate the best treatment plan for you
